AvenCell presented pre-clinical data on its CD123-directed allogeneic CAR T cell therapy at the American Association of Cancer Research Annual Meeting on April 18, 2023. The data showcases AVC-201, the first program that integrates AvenCell’s two proprietary platforms: Universal Switchable CAR and Allogeneic Cells, to create a potent and safe off-the-shelf CAR therapy that can be quickly activated and switched off. AVC-201 will soon be explored in the clinical setting for acute myeloid leukemia (AML).